Loading…
JAMP PERINDOPRIL/INDAPAMIDE is a brand name for Indapamide, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: JAMP Perindopril / Indapamide 2 mg / 0.625 mg (perindopril erbumine / indapamide) is indicated for the initial treatment of mild to moderate essential hypertension. JAMP Perindopril / Indapamide 4 mg / 1.25 mg and 8 mg / 2.5 mg are indicated in the treatment of mild to moderate essential hypertension in patients for…
Verbatim from this product's HC label. Tap a section to expand.
). The safety and efficacy of perindopril erbumine / indapamide in renovascular hypertension and in congestive heart failure have not been established and therefore, their use in this condition is not recommended. 1 Pediatrics (<18 years of age) The safety and effectiveness of perindopril erbumine / indapamide in children have not been established.
Its use in this age group, therefore, is not recommended. 2 Geriatrics (> 65 years of age) Although the blood pressure response and safety profile of perindopril erbumine / indapamide in patients >65 years old were comparable to those of the younger adult patients, greater sensitivity of some elderly patients cannot be ruled out.
73m2). JAMP Perindopril / Indapamide is contraindicated in: • Patients who are hypersensitive to this drug or to any ingredient in the formulation. For a complete listing, see the
). Treatment of progressive angioedema should be aggressive. Failing a rapid response to medical therapy, mechanical methods to secure an airway should be undertaken before massive oedema complicates oral or nasal intubation. Patients who respond to medical treatment should be observed carefully for a possible rebound phenomenon.
The onset of angioedema associated with the use of ACE inhibitors may be delayed for weeks or months. Patients may have multiple episodes of angioedema with long symptom-free intervals. Angioedema may occur with or without urticaria.
The incidence of angioedema during ACE inhibitor therapy has been reported to be higher in black than in non-black patients. There are reports that switching a patient to another ACE inhibitor could be followed by a recurrence of angioedema.
Because of the potential severity of this rare event, another ACE inhibitor should not be used in patients with a history of angioedema (see 2 CONTRAINDICATIONS). Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see 2 CONTRAINDICATIONS).
g. g. g. swelling of the airways or tongue, with or without respiratory impairment). Caution should be used when initiating ACE inhibitor therapy in patients already taking a mTOR, DPP-IV or NEP inhibitor or vice versa (see
, General). • Women who are pregnant, intend to become pregnant, or of childbearing potential who are not using adequate contraception (see 7 WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women). • Nursing women (see 7 WARNINGS AND PRECAUTIONS, Special Populations, Breast- feeding).
73m2). • Patients with hypokalemia. • Patients with severe hepatic impairment. • Patients with hepatic encephalopathy. • Combination with anti-arrhythmic agents causing torsade de pointes (see 9 DRUG INTERACTIONS – Drug-Drug Interactions).
• Patients with hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the total lactase deficiency as JAMP Perindopril / Indapamide contain lactose (see 7 WARNINGS AND PRECAUTIONS, Sensitivity/Resistance).
• Combination with sacubitril / valsartan due to an increased risk of angioedema. 73m2) (see 7 WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) and Renal, and 9 DRUG INTERACTIONS, Drug-Drug Interactions, Dual Blockade of the Renin-Angiotensin-System (RAS) with ACE inhibitors, ARBs or aliskiren-containing drugs).
• Patients with extracorporeal treatments leading to contact of blood with negatively charged surfaces (see 9 DRUG INTERACTIONS), • Patients with bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney (see 7 WARNINGS AND PRECAUTIONS, Renal).
3 SERIOUS WARNINGS AND PRECAUTIONS BOX Serious Warnings and Precautions • When used in pregnancy, angiotensin converting enzyme (ACE) inhibitors can cause injury or even death of the developing fetus. • When pregnancy is detected, JAMP Perindopril / Indapamide should be discontinued as soon as possible.
1 Dosing Considerations Dosage of JAMP Perindopril / Indapamide must be individualized and adjustment is required in the elderly, and in case of renal impairment. 5 mg are not for initial therapy and the dose should be determined by titration of the individual components.
JAMP
73m2). JAMP Perindopril / Indapamide is contraindicated in: • Patients who are hypersensitive to this drug or to any ingredient in the formulation. For a complete listing, see the 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND JAMP Perindopril / Indapamide (perindopril erbumine / indapamide) Page 5 of 70 Unclassified / Non classifié PACKAGING of the product monograph.
• Patients who are hypersensitive to other sulfonamide derivatives. • Patients with hereditary / idiopathic angioedema or a history of angioedema related to previous treatment with an angiotensin converting enzyme (ACE) inhibitor (see 7 WARNINGS AND PRECAUTIONS, General).
• Women who are pregnant, intend to become pregnant, or of childbearing potential who are not using adequate contraception (see 7 WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women). • Nursing women (see 7 WARNINGS AND PRECAUTIONS, Special Populations, Breast- feeding).
73m2). • Patients with hypokalemia. • Patients with severe hepatic impairment. • Patients with hepatic encephalopathy. • Combination with anti-arrhythmic agents causing torsade de pointes (see 9 DRUG INTERACTIONS – Drug-Drug Interactions).
• Patients with hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the total lactase deficiency as JAMP Perindopril / Indapamide contain lactose (see 7 WARNINGS AND PRECAUTIONS, Sensitivity/Resistance).
• Combination with sacubitril / valsartan due to an increased risk of angioedema. 73m2) (see 7 WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) and Renal, and 9 DRUG INTERACTIONS, Drug-Drug Interactions, Dual Blockade of the Renin-Angiotensin-System (RAS) with ACE inhibitors, ARBs or aliskiren-containing drugs).
• Patients with extracorporeal treatments leading to contact of blood with negatively charged surfaces (see 9 DRUG INTERACTIONS), • Patients with bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney (see 7 WARNINGS AND PRECAUTIONS, Renal).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Indapamide in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
2 Recommended Dose and Dosage Adjustment Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure elevation and salt restriction. The dosage of other antihypertensive agents being used with JAMP Perindopril / Indapamide may need to be adjusted.
The presence of food in the gastrointestinal tract reduces the bioavailability of perindoprilat. Pediatrics (<18 years) Health Canada has not authorized an indication for pediatric use. 4 Administration JAMP Perindopril / Indapamide should be taken once daily, preferably in the morning before a meal (see 9 DRUG INTERACTIONS – Drug-Food Interactions).
625 mg: 1 tablet per day as a single dose. 25 mg. 5 mg may be substituted if the titrated doses and dosing schedule can be achieved by the fixed combination (see 1 INDICATIONS and 7 WARNINGS AND PRECAUTIONS). The elderly Treatment should be initiated after considering blood pressure response and renal function.
73m2) (see 2 CONTRAINDICATIONS). 73m2) (see 2 CONTRAINDICATIONS). 25 mg should start with the adequate dosage of the combination of the individual components. Caution should be exercised especially in the elderly patients as greater sensitivity in the elderly cannot be ruled out.
73m2, no dose modification is required. Usual medical follow-up will include frequent monitoring of creatinine and potassium levels. 5 Missed Dose If a dose is missed, a double dose should not be taken; the patient should just carry on with the next dose at the normal time.
5 OVERDOSAGE The most likely adverse event in case of JAMP Perindopril / Indapamide overdose is hypotension with nausea, vomiting, cramps, dizziness, sleepiness, mental confusion, polyuria or oliguria which may progress to anuria. Electrolytes and water disturbances may occur.
The first measure is to rapidly eliminate ingested JAMP Perindopril / Indapamide by gastric lavage and / or administration of activated charcoal. Fluid and electrolyte balance should then be restored. If marked hypotension is produced, place the patient in a supine position with the head lower than the rest of the body.
9% sodium chloride or use any other method of volume expansion. Perindoprilat, the active form of perindopril, can be dialysed (see 10 CLINICAL PHARMACOLOGY, Pharmacokinetics). For management of a suspected drug overdose, contact your regional poison control centre.
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING Table 1 – […]